Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

TriSalus Life Sciences (TLSIW) Accounts Payables (2022 - 2025)

TriSalus Life Sciences' Accounts Payables history spans 4 years, with the latest figure at $3.0 million for Q4 2025.

  • For Q4 2025, Accounts Payables rose 32.01% year-over-year to $3.0 million; the TTM value through Dec 2025 reached $3.0 million, up 32.01%, while the annual FY2025 figure was $3.0 million, 32.01% up from the prior year.
  • Accounts Payables reached $3.0 million in Q4 2025 per TLSIW's latest filing, down from $3.8 million in the prior quarter.
  • In the past five years, Accounts Payables ranged from a high of $4.9 million in Q4 2022 to a low of $765244.0 in Q2 2022.
  • Average Accounts Payables over 4 years is $2.3 million, with a median of $2.1 million recorded in 2024.
  • Peak YoY movement for Accounts Payables: surged 248.94% in 2023, then tumbled 32.94% in 2024.
  • A 4-year view of Accounts Payables shows it stood at $4.9 million in 2022, then plummeted by 31.45% to $3.4 million in 2023, then tumbled by 32.94% to $2.3 million in 2024, then surged by 32.01% to $3.0 million in 2025.
  • Per Business Quant, the three most recent readings for TLSIW's Accounts Payables are $3.0 million (Q4 2025), $3.8 million (Q3 2025), and $1.9 million (Q2 2025).